News

The randomized, 120-patient study compared the combinations of Avastin (bevacizumab) plus Tarceva (erlotinib), and Avastin plus chemotherapy, to chemotherapy alone in patients with recurrent or refractory non-small cell

Computational drug design company Locus has successfully applied its novel technology in six external collaborations to date, which have demonstrated significant advantages in terms of novelty, cost and

The phase IIb clinical trial is an outpatient, multi-center, randomized, double-blind, single-dose, placebo-controlled study in approximately 400 migraine patients with or without aura. Four doses will be evaluated

The data, presented at the 2006 American Society of Clinical Oncology (ASCO) annual meeting, add to the growing body of evidence supporting the vaccine’s ability to provide strong

Under the terms of the agreement, the two companies will jointly evaluate and develop a pool of Emergent BioSolution’s proprietary antigens as the basis of a multivalent subunit

The goal of the study is to more fully define the safety and efficacy of the AIR insulin system in patients with type 1 diabetes. This study is

The single-arm, non-randomized study included 74 patients with advanced disease who had previously failed a median of three systemic therapies. Patients were given 400mg of the HDAC inhibitor

The study demonstrated the effectiveness of AVI’s exon skipping technology in significantly delaying the onset of diabetes and in reversing the disease after onset. This work validates the

The deal represents the second major collaboration for Genelabs based on its hepatitis C virus (HCV) drug delivery platform. Under the terms of the agreement, Genelabs is eligible